drugset / Trial / NCT04050800
Carbon-11 Butanol: Whole Body Radiochemical and Radiation Safety
NaSingle-groupOpen-labelBasic science
Summary
This will be a Phase 1, open label, imaging study of radiochemical and radiation safety in healthy volunteers. Using positron emission tomography (PET) and in-line computed tomography (CT), the whole body (WB) biokinetics of Carbon-11 butanol will be quantified with serial scans acquired every 3 minutes for two hours. Vital signs (VS), electrocardiograms (ECGs) and clinical laboratory tests of intrernal organ function will be acquired before and at several timepoints after administration of the radiopharmaceutical. Radiation exposures will be estimated with the MIRD Formalism.
Timeline
- Start
- 2020-09-17
- Primary completion
- 2020-12-29
- Completion
- 2021-01-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carbon 11 Butanol | Diagnostic / imaging agent | 555 mbq | Intravenous |